Skip to main content

Monkeys Develop Protective Antibodies to SARS-CoV-2

A small study of macaques finds they don’t develop a coronavirus infection the second time they are exposed, supporting the idea of using plasma from recovered patients as a treatment for COVID-19.

Written byKatarina Zimmer
| 5 min read
coronavirus covid-19 sars-cov-2 antibodies plasma therapy b cells monkey macaques

Register for free to listen to this article
Listen with Speechify
0:00
5:00

ABOVE: © ISTOCK.COM, SELVANEGRA

Whether people develop immunity to SARS-CoV-2 after being infected once is a pressing question for policymakers, public health professionals, and everyone affected by the spreading COVID-19 pandemic. It’s of particular interest to several research groups and companies currently developing plasma therapies, whereby antibody-containing blood plasma is extracted from recovered patients and administered to patients with severe cases to help them fight off the infection.

Now, a study in monkeys provides some clues. Three rhesus macaques did not develop a second infection after recovering from a first exposure to the coronavirus and being reexposed to SARS-CoV-2, suggesting that primates are capable of developing at least some short-term immunity to the pathogen. The research, posted as a preprint to bioRxiv March 14, has yet to undergo peer review. To the authors, the results indicate that reports of some COVID-19 survivors being “re-infected” a second time can be explained ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • katya katarina zimmer

    After a year teaching an algorithm to differentiate between the echolocation calls of different bat species, Katarina decided she was simply too greedy to focus on one field of science and wanted to write about all of them. Following an internship with The Scientist in 2017, she’s been happily freelancing for a number of publications, covering everything from climate change to oncology. Katarina is a news correspondent for The Scientist and contributes occasional features to the magazine. Find her on Twitter @katarinazimmer and read her work on her website.

    View Full Profile

Related Topics

Related articles background image
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Improving rAAV Production for Viral Vector Manufacturing

Improving rAAV Production for Viral Vector Manufacturing

cytiva logo
Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Miltenyi
Scientist holding a clear 384-well PCR microplate in a laboratory

What Dictates PCR Success Before Amplification Begins?

Integra Logo
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems

Products

Sino Biological Logo

Sino Biological Launches European Newsletter Campaign with Exclusive Welcome Gifts

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo